Azole resistance among Candida and Aspergillus species is one of the greatest challenges to clinical success, followed by echinocandin and multidrug resistance among some Candida species, particularly Candida glabrata.8 The spread of agriculturally derived azole-resistant Aspergillus fumigatus and emerging threats, such as multidrug-resistant Candida auris, are also a cause for concern.8
As much as 30–50% of antifungal prescriptions could be optimised or are inappropriate.9 Overprescribing of antifungal agents puts patients at great risk of drug toxicities and drug interactions, and has the potential to select for resistant fungi.9